Sky-high prices for orphan drugs may be causing insurers considerable concern, yet a slight majority continue to believe they can manage the costs, according to a new survey.

To wit, just 2 percent of beneficiaries covered by the surveyed plans have an orphan disease, which is defined as an ailment that afflicts 200,000 or fewer people. But rising prices for orphan drugs now account for roughly 9 percent of their total drug expenses. As a result, 77 percent of the payers say they are “extremely concerned” and 30 percent are “moderately concerned.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy